1. B. Botulinum toxin has no ability to inhibit esterase (A) or inhibit enzymes involved in the acetylcholine synthetic pathways (C), nor does it possess mus-carinic receptor blocking properties (D).
2. C. Thalidomide caused a high incidence of pho-comelia, particularly in Europe, where it was approved as a sedative agent. There is no definitive evidence associating teratogenic activity with the other compounds.
3. E. Interferon-a-2b is a recombinant product (A). Mycophenolate mofetil is derived from a Penicillium sp. (B). Methotrexate and 6-thioguanine (C and D) are totally synthesized.
4. C. Hydroquinone inhibits the enzyme tyrosine ki-nase, which converts tyrosine to melanin. It also damages melanocytes. Becaplermin (A) is a recombinant human platelet-derived growth factor that is useful in enhancing wound healing. Etanercept (B) is a recombinant fusion protein approved for treatment of psoriatic arthritis and rheumatoid arthritis. Botulinum toxin (D) is a purified form of botu-linum toxin type A approved for therapy of bleph-arospasm and strabismus.
Was this article helpful?
Thank you for deciding to learn more about the disorder, Osteoarthritis. Inside these pages, you will learn what it is, who is most at risk for developing it, what causes it, and some treatment plans to help those that do have it feel better. While there is no definitive “cure” for Osteoarthritis, there are ways in which individuals can improve their quality of life and change the discomfort level to one that can be tolerated on a daily basis.